RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

opioid-induced deaths continue to rise:

http://www.ama-assn.org/ams/pub/amawire/2013-february-27/2013-february-27-physician.shtml

The bag-holders have to decide whether they are happy with pennies on the dollar, or whether they want to bring a low-impact forward to target opioid-induced RD. Efficacy has been established, and this could be a block-buster. It is a more focused drug development program than Varney's ill-fated and foolish SA gambit.

If it is accurate that Varney looked high and low and couldn't find a buyer, it's not clear to me that this new group is going to have any more success. Yes, Varney may have disregarded low-ball offers, but it isn't clear that these low-ball offers are any more attractive to the people running things now.